Ocular surface toxicity associated with topical interferon α-2b [5]

British Journal of Ophthalmology

Volumn 91, Issue 8, 2007, Pages 1087-1088

  Aldave, Anthony J ^a,b   Nguyen, Anne ^a  

^a UCLA MEDICAL CENTER   (United States)

^b JULES STEIN EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; MITOMYCIN;

CATARACT EXTRACTION; CONJUNCTIVA EPITHELIUM; CONJUNCTIVA TUMOR; CORNEA EPITHELIUM; CRYOTHERAPY; DRUG WITHDRAWAL; EYE TOXICITY; HUMAN; LETTER; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

ADMINISTRATION, TOPICAL; ANTINEOPLASTIC AGENTS; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; CONJUNCTIVAL NEOPLASMS; EPITHELIUM, CORNEAL; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 34547208827     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.107482     Document Type: Letter

References (21)

1. Tunc M, Char DH, Crawford B, et al. Intraepithelial and invasive squamous cell carcinoma of the conjunctiva: analysis of 60 cases. Br J Ophthalmol 1999;83:98-103.
2. Frucht-Pery J, Rozenman Y, Pe'er J. Topical mitomycin-C for partially excised conjunctival squamous cell carcinoma. Ophthalmology 2002;109:548-52.
3. Rozenman Y, Frucht-Pery J. Treatment of conjunctival intraepithelial neoplasia with topical drops of mitomycin C. Cornea 2000;19:1-6.
4. Smith M, Trousdale MD, Rao NA, et al. Lack of toxicity of a topical recombinant interferon alpha. Cornea 1989;8:58-61.
5. Maskin SL. Regression of limbal epithelial dysplasia with topical interferon. Arch Ophthalmol 1994;112:1145-6.
6. Vann RR, Karp CL. Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia. Ophthalmology 1999;106:91-7.
7. Schechter BA, Schrier A, Nagler RS, et al. Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b. Cornea 2002;21:6-11.
8. Karp CL, Moore JK, Rosa RH Jr. Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b. Ophthalmology 2001;108:1093-8.
9. Hu FR, Wu MJ, Kuo SH. Interferon treatment for corneolimbal squamous dysplasia. Am J Ophthalmol 1998;125:118-19.
10. Boehm MD, Huang AJ. Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b. Ophthalmology 2004;111:1755-61.
11. Di Pascuale MA, Espana EM, Tseng SC. A case of conjunctiva-cornea intraepithelial neoplasia successfully treated with topical mitomycin C and interferon alfa-2b in cycles. Cornea 2004;23:89-92.
12. Holcombe DJ, Lee GA. Topical interferon alfa-2b for the treatment of recalcitrant ocular surface squamous neoplasia. Am J Ophthalmol 2006;142:568-71.
13. Heigle T, Stulting RD, Palay DA. Treatment of recurrent conjunctival epithelial neoplasia with topical mitomycin C. Am J Ophthalmol 1997;124:397-9.
14. Wu K, Hong SJ, Huang HT, et al. Toxic effects of mitomycin-C on cultured corneal keratocytes and endothelial cells. J Ocul Pharmacol Ther 1999;15:401-11.
15. Gupta S, Basti S. Corneoscleral, ciliary body, and vitreoretinal toxicity after excessive instillation of mitomycin C. Am J Ophthalmol 1992;114:503-4.
16. Kobayashi A, Yoshita T, Uchiyama K, et al. Successful management of conjunctival intraepithelial neoplasia by interferon alpha-2b. Jpn J Ophthalmol 2002;46:215-17.
17. Schechter BA. Conjunctival intraepithelial neoplasia. Ophthalmology 1999;106:1642-3.
18. Fracht HU, Harvey TJ, Bennett TJ. Transient corneal microcysts associated with interferon therapy. Cornea 2005;24:480-1.
19. Lazarus H, Hartnett ME, Reed MD, et al. Comparison of the prophylactic effects of 2-deoxycytidine and prednisolone for high-dose intravenous cytarabine-induced keratitis. Am J Ophthalmol 1987;104:476-80.
20. Hopen G, Mondino BJ, Johnson BL, et al. Corneal toxicity with systemic cytarabine. Am J Ophthalmol 1981;91:500-4.
21. Hertzog PJ, Hwang SY, Kola I. Role of interferons in the regulation of cell proliferation, differentiation, and development. Mol Reprod Dev 1994;39:226-32.